Evaluation of second-line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first-line cediranib

INTRODUCTION: Pivotal phase III trials have positioned angiogenesis inhibitors as first-line therapy for the management of most advanced or metastatic renal cell carcinomas (mRCC). Approaches to second-line therapy, however, remain more controversial with respect to drug selection and drug sequencin...

詳細記述

保存先:
書誌詳細
出版年:Can Urol Assoc J
主要な著者: Richter, Suzanne, Seah, Jo-An, Pond, Gregory R., Gan, Hui K., Mackenzie, Mary J., Hotte, Sebastien J., Mukherjee, Som D., Murray, Nevin, Kollmannsberger, Christian, Heng, Daniel, Haider, Masoom A., Halford, Robert, Ivy, S. Percy, Moore, Malcolm J., Sridhar, Srikala. S.
フォーマット: Artigo
言語:Inglês
出版事項: Canadian Medical Association 2014
主題:
Original Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4277518/
https://ncbi.nlm.nih.gov/pubmed/25553152
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5489/cuaj.2426
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料